PPARG and fatty liver disease: When incorporated into a high-carbohydrate diet at the same dose range, CAPE activated peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue, enhanced lipolysis and β-oxidation, promoted glucose uptake-related gene expression, and mitigated hepatic steatosis and inflammation, leading to reduced levels of ALT, AST, glucose (GLU), lactate dehydrogenase (LD), LDLC, and triglycerides (TG) [28].